Stock Watch: One Acquisition Does Not Make A Biotech M&A Boom
Pfizer’s Pandemic Success Finally Prompts A Transaction
Executive Summary
Another blow-out quarter from Pfizer provided the impetus for an acquisition. But the history of recent commercial-stage biotech transactions and the risky nature of all early-stage companies suggest that the floodgates will not burst open.
You may also be interested in...
Pfizer On Paxlovid: "There's Still A Long Way To Go"
Access to the COVID-19 treatment is broadening, but Pfizer says there is still work to do when it comes to getting the antiviral to patients quickly.
Stock Watch: Pfizer Caught Between The Pandemic And The Recovery
The pandemic is bad for Pfizer’s hospital products and traditional vaccine sales – but recovery is less good for Comirnaty and Paxlovid. Were investors right to be underwhelmed by Pfizer’s 2022 projections?
Stock Watch: Rare Diseases Beget Rare Profitability
Do rare disease drugs with tiny patient populations lie outside the profitability continuum that runs from small-molecule primary care products to specialist biologics?